MedPath
HSA Approval

THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL

SIN17027P

THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL

THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL

June 20, 2024

NYPRAX PHARMA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNYPRAX PHARMA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

INTRAVENOUS

Medical Information

L01AC01

Manufacturer Information

NYPRAX PHARMA PTE. LTD.

Thymoorgan Pharmazie GmbH

Active Ingredients

Thiotepa

15.0 mg/vial

Thiotepa

Documents

Package Inserts

THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION PI.pdf

Approved: June 20, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

THIOTEPA RIEMSER POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 15MG/VIAL - HSA Approval | MedPath